Our Mission:
Accelerating the prevention and cure of myeloma and improving
the quality of life for patients and families
I am a...
About Multiple Myeloma
Multiple myeloma starts in the bone marrow plasma cells. It weakens the immune system and can affect many parts of the body by causing the bone marrow to create dysfunctional antibodies and plasma cells. Living with or treating this disease means making complicated decisions, and this requires searching for reliable, current information on multiple myeloma.
How Can the International Myeloma Foundation Help?
The International Myeloma Foundation (IMF) connects people to what matters most — research that pushes the field forward, education that clarifies complex topics, support tailored to individual needs, and advocacy that amplifies every voice. Patients, care partners, healthcare professionals, and researchers can access the knowledge, resources, and community they need from the IMF to navigate life with myeloma.
This week’s blog covers the latest myeloma research from September-October 2026. It includes a review on BCMA-targeted immunotherapy in early relapsed/refractory multiple myeloma, a study that identifies spatial transcriptomics in suppressive, T-cell–excluded tumor microenvironment in extramedullary myeloma, and more. Additionally, get the latest on myeloma clinical trials, a recommendation from the European Medicine Agency’s CHMP, and a drug approval from the European Commission. READ THE BLOG.
El próximo grupo de apoyo, Las Voces de Mieloma (en español) será el martes 17 de noviembre, de 10:00 a. m. a 11:00 a. m. (hora del Pacífico). La ponente invitada será Stefania Mancia, APRN, enfermera de práctica avanzada certificada y especialista en hematología maligna y terapia celular. Ella dirige el Programa de Supervivencia en el departamento de Hematología Maligna y Terapia Celular del Moffitt Cancer Center, parte del Memorial Cancer Institute en el sur de Florida. El tema de la reunión será: Mitos sobre el mieloma: ¿verdadero, falso o depende? REGÍSTRESE AQUÍ.
On Friday, October 23, the European Commission (EC) approved an expanded indication for TECVAYLI® (teclistamab) monotherapy for adults with relapsed/refractory multiple myeloma (RRMM) who have received at least one prior therapy. The approval introduces another treatment option in the second-line setting, following the EC’s August 2026 approval of teclistamab in combination with daratumumab. The decision is supported by results from the phase 3 MajesTEC-9 trial (NCT05572515), which demonstrated significant improvements in progression-free survival (PFS) and overall survival (OS) compared with standard-of-care regimens. READ THE NEWS ARTICLE.
The IMF offers Myeloma Community Workshops (MCWs), which are shorter, yet still robust, programs in cities across the U.S. Learn more about an MCW in Phoenix, CA, or about an upcoming Virtual MCW. LEARN MORE HERE.
When you volunteer to organize a community fundraiser for the IMF, you receive support and guidance from the IMF's Development Team. Whether it's a 5K Walk/Run, a bake sale, or a simple letter-writing campaign, we're here to help you.
